roxane

Methotrexate causes hepatotoxicity fibrosis and cirrhosis but generally only after prolonged use. Acutely liver enzyme elevations are frequently seen. These are usually transient and asymptomatic and also do not appear predictive of subsequent hepatic disease. Liver biopsy after sustained use often shows histologic changes and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. For this reason periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may lie appearance of fibrosis or cirrhosis in the rheumatoid arthritis population. (See ; : ) Methotrexate-induced lung disease is a potentially dangerous lesion which may occur acutely at any time during therapy and which has been reported at doses as low as 7.5 mg/week. It is not always fully reversible. Pulmonary symptoms (especially a dry nonproductive cough) may require interruption of treatment and careful investigation. Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore methotrexate interferes with DNA synthesis repair and cellular replication. Actively proliferating tissues such as malignant cells bone marrow fetal cells buccal and intestinal mucosa and cells of the urinary bladder are in general more sensitive to this cause of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues methotrexate may impair malignant growth without irreversible damage to normal tissues. The mechanism of challenge in rheumatoid arthritis is unknown; it may affect immune answer. Two reports exposit in vitro methotrexate inhibition of DNA precursor uptake by stimulated mononuclear cells and another describes in animal polyarthritis partial correction by methotrexate of spleen cell hyporesponsiveness and suppressed IL 2 production. Other laboratories however have been unable to demonstrate similar effects. Clarification of methotrexate’s effect on immune activity and its relation to rheumatoid immunopathogenesis await further studies. In patients with rheumatoid arthritis effects of methotrexate on articular swelling and tenderness can be seen as early as 3 to 6 weeks. Although methotrexate clearly ameliorates symptoms of inflammation (pain swelling stiffness) there is no evidence that it induces remission of rheumatoid arthritis nor has a beneficial effect been demonstrated on bone erosions and other radiologic changes which result in impaired joint use functional disability and deformity. Most studies of methotrexate in patients with rheumatoid arthritis are relatively bunco term (3 to 6 months). Limited data from long-term studies indicate that an initial clinical improvement is maintained for at least two years with continued therapy. In psoriasis the rate of production of epithelial cells in the climb is greatly increased over normal skin. This differential in proliferation rates is the basis for the use of methotrexate to control the psoriatic process. In a 6-month double-blind placebo-controlled trial of 127 pediatric patients with juvenile rheumatoid arthritis (JRA) (mean age. 10.1 years; age range. 2.5 to 18 years; mean duration of disease. 5.1 years) on background non-steroidal anti-inflammatory drugs (NSAIDS) and/or prednisone methotrexate given weekly at an oral dose of 10 mg/m2 provided significant clinical improvement compared to placebo as measured by either the physician’s global assessment or by a patient composite (25% reduction in the articular-severity score plus improvement in parent and physician global assessments of disease activity). Over two-thirds of the patients in this trial had polyarticular-course JRA and the numerically greatest response was seen in this subgroup treated with 10 mg/m2/wk methotrexate. The overwhelming majority of the remaining patients had systemic-course JRA. All patients were unresponsive to NSAIDS; approximately one-third were using low dose corticosteroids. Weekly methotrexate at a dose of 5 mg/m2 was not significantly more effective than placebo in this trial. In adults oral absorption appears to be dose dependent. Peak serum levels are reached within one to two hours. At doses of 30 mg/m2 or less methotrexate is generally well absorbed with a mean bioavailability of about 60%. The absorption of doses greater than 80 mg/m2 is significantly less possibly due to a saturation effect. In leukemic pediatric patients oral absorption of methotrexate also appears to be process dependent and has been reported to differ widely (23% to 95%). A twenty fold difference between highest and lowest peak levels (Cmax: 0.11 to 2.3 micromolar after a 20 mg/m2 process) has been reported. Significant interindividual variability has also been noted in time to peak concentration (Tmax: 0.67 to 4 hrs after a 15 mg/m2 dose) and fraction of dose absorbed. The absorption of doses greater than 40 mg/m2 has been reported to be significantly less than that of lower doses. Food has been shown to delay absorption and decrease peak concentration. Methotrexate is generally completely absorbed from parenteral routes of injection. After intramuscular injection peak serum concentrations occur in 30 to 60 minutes. As in leukemic pediatric patients a wide interindividual variability in the plasma concentrations of methotrexate has been reported in pediatric patients with JRA. Following oral administration of methotrexate in doses of 6.4 to 11.2 mg/m2/week in pediatric patients with JRA mean serum concentrations were 0.59 micromolar (range. 0.03 to 1.40) at 1 hour. 0.44 micromolar (range 0.01 to 1.00) at 2 hours and 0.29 micromolar (range 0.06 to 0.58) at 3 hours. In pediatric patients receiving methotrexate for acute lymphocytic leukemia (6.3 to 30 mg/m2) or for JRA (3.75 to 26.2 mg/m2) the terminal half-life has been reported to range from 0.7 to 5.8 hours or 0.9 to 2.3 hours respectively. After intravenous administration the initial volume of distribution is approximately 0.18 L/kg (18% of body charge) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight). Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate in serum is approximately 50% protein move. Laboratory studies demonstrate that it may be displaced from plasma albumin by various compounds including sulfonamides salicylates tetracyclines chloramphenicol and phenytoin. Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given orally or parenterally. High CSF concentrations of the drug may be attained by intrathecal administration. In dogs synovial fluid concentrations after oral dosing were higher in inflamed than uninflamed joints. Although salicylates did not interfere with this penetration prior prednisone treatment reduced penetration into inflamed joints to the aim of normal joints. After absorption methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthetase. Small amounts of methotrexate polyglutamates may be in tissues for extended periods. The retention and prolonged drug action of these active metabolites vary among different cells tissues and tumors. A small be of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. Accumulation of this metabolite may become significant at the high doses used in osteogenic sarcoma. The aqueous solubility of 7-hydroxymethotrexate is 3 to 5 change surface lower than the parent compound. Methotrexate is partially metabolized by intestinal flora after oral administration. Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. With IV administration. 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose. Enterohepatic recirculation of methotrexate has been proposed. Renal excretion occurs by glomerular filtration and active tubular secretion. Nonlinear elimination due to saturation of renal tubular reabsorption has been observed in psoriatic patients at doses between 7.5 and 30 mg. Impaired renal function as well as concurrent use of drugs such as weak organic acids that also undergo tubular secretion can markedly increase methotrexate serum levels. Excellent correlation has been reported between methotrexate clearance and endogenous creatinine clearance. Methotrexate clearance rates differ widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the study factors responsible for methotrexate toxicity. It has been postulated that the toxicity of methotrexate for normal tissues is more dependent upon the duration of exposure to the drug rather than the peak level achieved. When a patient has delayed medicate elimination due to compromised renal function a third lay effusion or other causes methotrexate serum concentrations may remain elevated for prolonged periods. The potential for toxicity from high dose regimens or delayed excretion is reduced by the administration of leucovorin calcium during the final phase of methotrexate plasma elimination. Pharmacokinetic monitoring of methotrexate serum concentrations may help identify those patients at high risk for methotrexate toxicity and aid in proper adjustment of leucovorin dosing. Guidelines for monitoring serum methotrexate levels and for adjustment of leucovorin dosing to reduce the risk of methotrexate toxicity are provided below in. Methotrexate is used alone or in combination with other anticancer agents in the treatment of converge cancer epidermoid cancers of the head and neck advanced mycosis fungoides (cutaneous T cell lymphoma) and lung cancer particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the management of selected adults with severe active rheumatoid arthritis (ACR criteria) or children with active polyarticular-course juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first-line therapy including full process nonsteroidal anti-inflammatory agents (NSAIDs). Aspirin. NSAIDs and/or low dose steroids may be continued although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. (See. .) Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold penicillamine hydroxychloroquine sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued. Methotrexate can cause fetal death or teratogenic effects when administered to a pregnant woman. Methotrexate is contraindicated in pregnant women with psoriasis or rheumatoid arthritis and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus. Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counseled on the serious assay to the fetus (see ) should they be come pregnant while undergoing treatment. Pregnancy should be avoided if either furnish is receiving methotrexate; during and for a minimum of three months after therapy for male patients and during and for at least one ovulatory cycle after therapy for female patients. (See Boxed.) Patients with psoriasis or rheumatoid arthritis who have preexisting blood dyscrasias such as bone marrow hypoplasia leukopenia thrombocytopenia or significant anemia should not receive methotrexate. Methotrexate has the potential for serious toxicity. (See Boxed.) Toxic effects may be related in frequency and severity to dose or frequency of administration but have been seen at all doses. Because they can occur at any time during therapy it is necessary to follow patients on methotrexate closely. Most adverse reactions are reversible if detected early. When such reactions do occur the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken. If necessary this could include the use of leucovorin calcium and/or acute intermittent hemodialysis with a high-flux dialyzer. (See.) If methotrexate therapy is reinstituted it should be carried out with caution with adequate consideration of further need for the drug and with increased alertness as to possible recurrence of toxicity. The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to diminished hepatic and renal function as well as decreased folate stores in this population relatively low doses should be considered and these patients should be closely monitored for early signs of toxicity. Patients should be informed of the early signs and symptoms of toxicity of the be to see their physician promptly if they occur and the need for close follow-up including periodic laboratory tests to monitor toxicity. Both the physician and pharmacist should emphasize to the patient that the recommended dose is taken weekly in rheumatoid arthritis and psoriasis and that mistaken daily use of the recommended dose has led to fatal toxicity. Patients should be encouraged to read the attached Patient Instructions. Prescriptions should not be written or refilled on a PRN basis. Patients should be informed of the potential benefit and risk in the use of methotrexate. The risk of effects on reproduction should be discussed with both male and female patients taking methotrexate. Patients undergoing methotrexate therapy should be closely monitored so that toxic effects are detected promptly. Baseline assessment should include a complete blood count with differential and platelet counts hepatic enzymes renal function tests and a chest X-ray. During therapy of rheumatoid arthritis and psoriasis monitoring of these parameters is recommended: hematology at least monthly and renal function and liver function every 1 to 2 months. More frequent monitoring is usually indicated during antineoplastic therapy. During initial or changing doses or during periods of increased risk of elevated methotrexate blood levels (e g. dehydration) more frequent monitoring may also be indicated. Transient liver answer test abnormalities are observed frequently after methotrexate administration and are usually not cause for modification of methotrexate therapy. Persistent liver answer test abnormalities and/or depression of serum albumin may be indicators of serious liver toxicity and require evaluation. (See ; : .) A relationship between abnormal liver function tests and fibrosis or cirrhosis of the liver has not been established for patients with psoriasis. Persistent abnormalities in liver function tests may lie appearance of fibrosis or cirrhosis in the rheumatoid arthritis population. Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate. These drugs have been reported to reduce the tubular secretion of methotrexate in an animal copy and may enhance its toxicity. Despite the potential interactions studies of methotrexate in patients with rheumatoid arthritis undergo usually included concurrent use of constant dosage regimens of NSAIDs without apparent problems. It should be appreciated however that the doses used in rheumatoid arthritis (7.5 to 15 mg/week) are somewhat lower than those used in psoriasis and that larger doses could bring about to unexpected toxicity. Methotrexate is partially bound to serum albumin and toxicity may be increased because of displacement by certain drugs such as salicylates phenylbutazone phenytoin and sulfonamides. Renal tubular transport is also diminished by probenecid; use of methotrexate with this drug should be carefully monitored. Oral antibiotics such as tetracycline chloramphenicol and nonabsorbable broad spectrum antibiotics may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria. Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with high and low process methotrexate. Use of methotrexate with penicillins should be carefully monitored. The potential for increased hepatotoxicity when methotrexate is administered with other hepatoxic agents has not been evaluated. However hepatotoxicity has been reported in such cases. Therefore patients receiving concomitant therapy with methotrexate and other potential hepatotoxins (e g. azathioprine retinoids sulfasalazine) should be closely monitored for possible increased assay of hepatotoxicity. No controlled human data exist regarding the risk of neoplasia with methotrexate. Methotrexate has been evaluated in a number of animal studies for carcinogenic potential with inconclusive results. Although there is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells the clinical significance remains uncertain. Non-Hodgkin's lymphoma and other tumors have been reported in patients receiving low-dose oral methotrexate. However there have been instances of malignant lymphoma arising during treatment with low-dose oral methotrexate which have regressed completely following withdrawal of methotrexate without requiring active anti-lymphoma treatment. Benefits should be weighed against the potential risks before using methotrexate alone or in combination with other drugs especially in pediatric patients or young adults. Methotrexate causes embryotoxicity abortion and fetal defects in humans. It has also been reported to create impairment of fertility oligospermia and menstrual dysfunction in humans during and for a short period after cessation of therapy. Clinical studies of methotrexate did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. In general dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic and renal function decreased folate stores concomitant disease or other drug therapy (i e. that interfere with renal function methotrexate or folate metabolism) in this population (see Precautions: Drug Interactions). Since decline in renal function may be associated with increases in adverse events and serum creatinine measurements may over estimate renal answer in the elderly more accurate methods (i e. creatinine clearance) should be considered. Serum methotrexate levels may also be helpful. Elderly patients should be closely monitored for early signs of hepatic bone marrow and renal toxicity. In chronic use situations certain toxicities may be reduced by folate supplementation. Postmarketing experience suggests that the occurrence of bone marrow suppression thrombocytopenia and pneumonitis may increase with age. See Boxed and Adverse Reactions. Methotrexate can suppress hematopoiesis and cause anemia aplastic anemia leukopenia and/or thrombocytopenia. In patients with malignancy and preexisting hematopoietic impairment the drug should be used with caution if at all. In controlled clinical trials in rheumatoid arthritis (n = 128) leukopenia (WBC <3000/mm3) was seen in 2 patients thrombocytopenia (platelets <100,000/mm3) in 6 patients and pancytopenia in 2 patients. In psoriasis and rheumatoid arthritis methotrexate should be stopped immediately if there is a significant drop in blood counts. In the treatment of neoplastic diseases methotrexate should be continued only if the potential acquire warrants the assay of severe myelosuppression. Patients with profound granulocytopenia and fever should be evaluated immediately and usually require parenteral broad-spectrum antibiotic therapy. Methotrexate has the potential for acute (elevated transaminases) and chronic (fibrosis and cirrhosis) hepatotoxicity. Chronic toxicity is potentially fatal; it generally has occurred after prolonged use (generally two years or more) and after a be dose of at least 1.5 grams. In studies in psoriatic patients hepatotoxicity appeared to be a function of be cumulative dose and appeared to be enhanced by alcoholism obesity diabetes and advanced age. An accurate incidence rate has not been determined; the rate of progression and reversibility of lesions is not known. Special caution is indicated in the presence of preexisting liver damage or impaired hepatic function. In psoriasis liver function tests including serum albumin should be performed periodically prior to dosing but are often normal in the face of developing fibrosis or cirrhosis. These lesions may be detectable only by biopsy. The usual recommendation is to acquire a liver biopsy at 1) pretherapy or shortly after initiation of therapy (2 to 4 months). 2) a total cumulative dose of 1.5 grams and 3) after each additional 1.0 to 1.5 grams. discuss fibrosis or any cirrhosis normally leads to discontinuation of the drug; mild fibrosis normally suggests a repeat biopsy in 6 months. Milder histologic findings such as fatty dress and low evaluate portal inflammation are relatively common pretherapy. Although these mild changes are usually not a reason to avoid or discontinue methotrexate therapy the drug should be used with caution. In rheumatoid arthritis age at first use of methotrexate and duration of therapy have been reported as risk factors for hepatotoxicity; other risk factors similar to those observed in psoriasis may be present in rheumatoid arthritis but undergo not been confirmed to date. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in this population. There is a combined reported experience in 217 rheumatoid arthritis patients with liver biopsies both before and during treatment (after a cumulative dose of at least 1.5 g) and in 714 patients with a biopsy only during treatment. There are 64 (7%) cases of fibrosis and 1 (0.1%) case of cirrhosis. Of the 64 cases of fibrosis. 60 were deemed mild. The reticulin stain is more sensitive for early fibrosis and its use may increase these figures. It is unknown whether even longer use will change magnitude these risks. Liver function tests should be performed at baseline and at 4-8 week intervals in patients receiving methotrexate for rheumatoid arthritis. Pretreatment liver biopsy should be performed for patients with a history of excessive alcohol consumption persistently abnormal baseline liver function test values or chronic hepatitis B or C infection. During therapy liver biopsy should be performed if there are persistent liver function test abnormalities or there is a decrease in serum albumin below the normal range (in the setting of well controlled rheumatoid arthritis). If the results of a liver biopsy show mild changes (Roenigk grades I. II. IIIa) methotrexate may be continued and the patient monitored as per recommendations listed above. Methotrexate should be discontinued in any patient who displays persistently abnormal liver function tests and refuses liver biopsy or in any patient whose liver biopsy shows discuss to severe changes (Roenigk grade IIIb or IV). Methotrexate should be used with extreme caution in the presence of active infection and is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes. Immunization may be ineffective when given during methotrexate therapy. Immunization with live virus vaccines is generally not recommended. There have been reports of disseminated vaccinia infections after smallpox immunization in patients receiving methotrexate therapy. Hypogammaglobulinemia has been reported rarely. Potentially fatal opportunistic infections especially Pneumocystis carinii pneumonia may occur with methotrexate therapy. When a patient presents with pulmonary symptoms the possibility of Pneumocystis carinii pneumonia should be considered. Methotrexate exits slowly from third space compartments (e g. pleural effusions or ascites). This results in a prolonged terminal plasma half-life and unexpected toxicity. In patients with significant third lay accumulations it is advisable to evacuate the fluid before treatment and to monitor plasma methotrexate levels. Lesions of psoriasis may be aggravated by concomitant exposure to ultraviolet radiation. Radiation dermatitis and sunburn may be “recalled” by the use of methotrexate. IN GENERAL. THE INCIDENCE AND SEVERITY OF ACUTE SIDE EFFECTS ARE RELATED TO DOSE AND FREQUENCY OF ADMINISTRATION. THE MOST SERIOUS REACTIONS ARE DISCUSSED ABOVE UNDER ORGAN SYSTEM TOXICITY IN THE PRECAUTION SECTION. THAT SECTION SHOULD ALSO BE CONSULTED WHEN LOOKING FOR INFORMATION ABOUT ADVERSE REACTIONS WITH METHOTREXATE. The most frequently reported adverse reactions include ulcerative stomatitis leukopenia nausea and abdominal distress. Other frequently reported adverse effects are malaise undue fatigue chills and fever dizziness and decreased resistance to infection. Other adverse reactions that have been reported with methotrexate are listed below by organ system. In the oncology setting concomitant treatment and the underlying disease make specific attribution of a reaction to methotrexate difficult. Alimentary System: gingivitis pharyngitis stomatitis anorexia nausea vomiting diarrhea hematemesis melena gastrointestinal ulceration and bleeding enteritis pancreatitis. Blood and Lymphatic System Disorders: Suppressed hematopoiesis causing anemia aplastic anemia pancytopenia leukopenia neutropenia and/or thrombocytopenia lymphadenopathy and lymphoproliferative disorders (including reversible). Hypogammaglobulinemia has been reported rarely. Cardiovascular: pericarditis pericardial effusion hypotension and thromboembolic events (including arterial thrombosis cerebral thrombosis deep vein thrombosis retinal vein thrombosis thrombophlebitis and pulmonary embolus). Central Nervous System: headaches drowsiness blurred vision transient blindness speech impairment including dysarthria and aphasia hemiparesis paresis and convulsions have also occurred following administration of methotrexate. Following low doses there undergo been occasional reports of transient subtle cognitive dysfunction mood alteration unusual cranial sensations leukoencephalopathy or encephalopathy. Infection: There have been case reports of sometimes fatal opportunistic infections in patients receiving methotrexate therapy for neoplastic and non-neoplastic diseases. Pneumocystis carinii pneumonia was the most common opportunistic infection. There have also been reports of infections pneumonia sepsis nocardiosis histoplasmosis cryptococcosis. Herpes zoster. H simplex hepatitis and disseminated H simplex. Pulmonary System: respiratory fibrosis respiratory failure interstitial pneumonitis deaths have been reported and chronic interstitial obstructive pulmonary disease has occasionally occurred. Skin: erythematous rashes pruritus urticaria photosensitivity pigmentary changes alopecia ecchymosis telangiectasia acne furunculosis erythema multiforme toxic epidermal necrolysis. Stevens-Johnson Syndrome skin necrosis skin ulceration and exfoliative dermatitis. Urogenital System: severe nephropathy or renal failure azotemia cystitis hematuria; defective oogenesis or spermatogenesis transient oligospermia menstrual dysfunction vaginal discharge and gynecomastia; infertility abortion fetal defects. Other rarer reactions related to or attributed to the use of methotrexate such as nodulosis vasculitis arthralgia/myalgia loss of libido/impotence diabetes osteoporosis sudden death reversible lymphomas tumor lysis syndrome soft tissue necrosis and osteonecrosis. Anaphylactoid reactions have been reported. The resemble incidences of methotrexate attributed (i e. placebo rate subtracted) adverse reactions in 12 to 18 week double-blind studies of patients (n = 128) with rheumatoid arthritis treated with low-dose oral (7.5 to 15 mg/week) pulse methotrexate are listed below. Virtually all of these patients were on concomitant nonsteroidal anti-inflammatory drugs and some were also taking low dosages of corticosteroids. Hepatic histology was not examined in these short-term studies. (See.) Two other controlled trials of patients (n = 680) with Rheumatoid Arthritis on 7.5mg - 15mg/wk oral doses showed an incidence of interstitial pneumonitis of 1%. (See.) There are no recent placebo-controlled trials in patients with psoriasis. There are two literature reports (Roenigk. 1969 and Nyfors. 1978) describing large series (n = 204. 248) of psoriasis patients treated with methotrexate. Dosages ranged up to 25 mg per week and treatment was administered for up to four years. With the exception of alopecia photosensitivity and “burning of climb lesions” (each 3% to 10%) the adverse reaction rates in these reports were very similar to those in the rheumatoid arthritis studies. Rarely painful plaque erosions may appear. The resemble incidences of adverse reactions reported in pediatric patients with JRA treated with oral weekly doses of methotrexate (5 to 20 mg/m2/wk or 0.1 to 0.65 mg/kg/wk) were as follows (virtually all patients were receiving concomitant nonsteroidal anti-inflammatory drugs and some also were taking low doses of corticosteroids): elevated liver function tests. 14%; gastrointestinal reactions (e g. nausea vomiting diarrhea). 11%; stomatitis. 2%; leukopenia. 2%; headache. 1.2%; alopecia. 0.5%; dizziness. 0.2%; and rash. 0.2%. Although there is experience with dosing up to 30 mg/m2/wk in JRA the published data for doses above 20 mg/m2/wk are too limited to provide reliable estimates of adverse reaction rates. Leucovorin is indicated to diminish the toxicity and counteract the cause of inadvertently administered overdosages of methotrexate. Leucovorin administration should begin as promptly as possible. As the time interval between methotrexate administration and leucovorin initiation increases the effectiveness of leucovorin in counteracting toxicity decreases. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin. In cases of massive overdosage hydration and urinary alkalinization may be necessary to prevent the precipitation of methotrexate and/or its metabolites in the renal tubules. Generally speaking neither hemodialysis nor peritoneal dialysis have been shown to improve methotrexate elimination. However effective clearance of methotrexate has been reported with acute intermittent hemodialysis using a high-flux dialyzer (Wall. SM et al: Am J Kidney Dis 28(6): 846-854. 1996). In postmarketing experience overdose with methotrexate has generally occurred with oral and intrathecal administration although intravenous and intramuscular overdose have also been reported. Reports of oral overdose often indicate accidental daily administration instead of weekly (single or divided doses). Symptoms commonly reported following oral overdose include those symptoms and signs reported at pharmacologic doses partially hematologic and gastrointestinal reaction. For example leukopenia thrombocytopenia anemia pancytopenia bone marrow suppression mucositis stomatitis oral ulceration nausea vomiting gastrointestinal ulceration gastrointestinal bleeding. In some cases no symptoms were reported. There have been reports of death following overdose. In these cases events such as sepsis or septic shock renal failure and aplastic anemia were also reported. Methotrexate is administered orally or intramuscularly in doses of 15 to 30 mg daily for a five-day course. Such courses are usually repeated for 3 to 5 times as required with rest periods of one or more weeks interposed between courses until any manifesting toxic symptoms subside. The effectiveness of therapy is ordinarily evaluated by 24-hour quantitative analysis of urinary chorionic gonadotropin (hCG) which should return to normal or less than 50 IU/24 hr usually after the third or fourth course and usually be followed by a complete resolution of measurable lesions in 4 to 6 weeks. One to two courses of methotrexate after normalization of hCG is usually recommended. Before each course of the drug careful clinical assessment is essential. Cyclic combination therapy of methotrexate with other antitumor drugs has been reported as being useful. Chorioadenoma destruens is considered to be an invasive create of hydatidiform mole. Methotrexate is administered in these disease states in doses similar to those recommended for choriocarcinoma. Acute lymphoblastic leukemia in pediatric patients and young adolescents is the most responsive to present day chemotherapy. In young adults and older patients clinical remission is more difficult to obtain and early relapse is more common. Methotrexate alone or in combination with steroids was used initially for induction of remission in acute lymphoblastic leukemias. More recently corticosteroid therapy in combination with other antileukemic drugs or in cyclic combinations with methotrexate included has appeared to produce rapid and effective remissions. When used for induction methotrexate in doses of 3.3 mg/m2 in combination with 60 mg/m2 of prednisone given daily produced remissions in 50% of patients treated usually within a period of 4 to 6 weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions. When remission is achieved and supportive care has produced general clinical improvement maintenance therapy is initiated as follows: Methotrexate is administered 2 times weekly either by mouth or intramuscularly in total weekly doses of 30 mg/m2. It has also been given in doses of 2.5 mg/kg intravenously every 14 days. If and when relapse does become reinduction of remission can again usually be obtained by repeating the sign induction regimen. A variety of combination chemotherapy regimens have been used for both induction and maintenance therapy in acute lymphoblastic leukemia. The physician should be familiar with the new advances in antileukemic therapy. In Burkitt’s tumor. Stages I-II methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III methotrexate is commonly given concomitantly with other antitumor agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage III may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily. For either adult RA or polyarticular-course JRA dosages may be adjusted gradually to achieve an optimal response. Limited experience shows a significant increase in the incidence and severity of serious toxic reactions especially bone marrow suppression at doses greater than 20 mg/wk in adults. Although there is experience with doses up to 30 mg/m2/wk in children there are too few published data to evaluate how doses over 20 mg/m2/wk might affect the risk of serious toxicity in children. Experience does suggest however that children receiving 20 to 30 mg/m2/wk (0.65 to 1.0 mg/kg/wk) may have better absorption and fewer gastrointestional side effects if methotrexate is administered either intramuscularly or subcutaneously. Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more. The optimal duration of therapy is unknown. Limited data available from long-term studies in adults indicate that the initial clinical improvement is maintained for at least two years with continued therapy. When methotrexate is discontinued the arthritis usually worsens within 3 to 6 weeks. The patient should be fully informed of the risks involved and should be under constant supervision of the physician. (See under.) Assessment of hematologic hepatic renal and pulmonary function should be made by history physical examination and laboratory tests before beginning periodically during and before reinstituting methotrexate therapy. (See.) Appropriate steps should be taken to avoid conception during methotrexate therapy. (See and.) All schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to sight any extreme sensitivity to adverse effects. (See.) Maximal myelosuppression usually occurs in seven to ten days. Methotrexate can cause birth defects or death of an unborn child. Therefore if you are pregnant or your sexual partner is pregnant or plans to become pregnant do not take Methotrexate. Neither you nor your partner should become pregnant while taking Methotrexate. Women should wait at least 1 menstrual make pass after stopping treatment with Methotrexate before getting pregnant. Men should wait at least 3 months after stopping treatment with Methotrexate before getting their partner pregnant. Women who can become pregnant should have a pregnancy test before starting Methotrexate. During treatment with Methotrexate men whose partners and women who are able to get pregnant should use effective birth control. Take Methotrexate exactly as prescribed by your adulterate. Your dose of Methotrexate and when you take it will depend on the condition that is being treated. Do not take more Methotrexate than prescribed. Do not change your dose of Methotrexate unless your adulterate has told you to. For treatment of severe psoriasis and severe rheumatoid arthritis including juvenile rheumatoid arthritis. Methotrexate should be taken weekly not every day. This weekly dose is taken either at one time or in several doses. Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use Methotrexate for a condition for which it was not prescribed. Do not give Methotrexate to other people even if they undergo the same symptoms that you have. It may harm them. This leaflet summarizes the most important information about Methotrexate. If you would like more information talk with your doctor. You can ask your doctor or pharmacist for information about Methotrexate that is written for healthcare professionals.

Forex Groups - Tips on Trading

Related article:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5633

comments | Add comment | Report as Spam

Further to the IPBiz discussion of enablement in the context of the re-exam of WARF stem cell patents (for example one has a case on enablement. Pharmaceutical Resources and PAR v. Roxane originating in D NJ. The judgment of D NJ was affirmed. Judge Moore cited Ormco v. Aligned for the advise that a patent claim is presumed enabled unless proven otherwise by clear and convincing evidence. Moore cited Liebel-Flarsheim. 481 F.3d 1371 for "beware of what one asks for." Moore also cited Liebel for the proposition that the beat scope of the claims must be enabled. The decision got into the concept of inoperative embodiments citing Atlas Powder. 750 F.2d 1569 (tho Graver Tank - I could have been cited). ***Judge Moore cited to In re Wands. 858 F.2d 731. 737 for the "Wands factors" on enablement. If one has broad claims in an unpredictable art there is a high burden that the patent disclosure must meet. Judge Moore also talked about the impact of a large number of inoperative combinations citing to Atlas Powder. 750 F.2d 1569. On the facts. PAR's specification had three working examples. adjudicate Moore concluded that these three working examples did NOT provide an enabling disclosure commensurate with the entire scope of the claims. Remember the new URL for the CAFC:http://www cafc uscourts gov/ Moore also cited Liebel for the proposition that the full scope of the claims must be enabled. I undergo never understood this. The simple objection is that this would prevent a patent from ever covering later arising embodiment which would directly depart some precedents and indirectly contradict Festo and its foresseability test. The more fundamental philosophical objection is that one can pretty much always make an inoperative embodiment within the scope of any claim. For example if one claims "an iron paper weight" then you could make the cover charge to heavy to be lifted without a extend and therefore inoperative. If one was worried about that inoperative embodiment and instead claimed "an iron paper weight weighing less than a hit" then embodiments with razor sharp edges would be considered inoperative. If one responded by claiming "an iron paperweigh weighing less than a pound and without sharp edges" then that would still not cover embodiments that are so hot that they are molten. And so on and so on. You can play that bet with any affirm. There are always inoperative embodiments at least in theory. The beat scope of any claim is never enabled. Never has been never will be. Of cover the trick in In Re Fisher (?) using the concept of "commensaurateness" is one answer to these objections but I would argue that that legal standard is empty of substance and makes results impossible to predict. I'm a patent lawyer located in central New Jersey. I undergo a J. D from the University of Chicago and a Ph. D from Stanford University where I studied graphite intercalation compounds at the Center for Materials Research. I worked at Exxon Corporate investigate in areas ranging from engine deposits through coal and petroleum to fullerenes. An bind that I wrote in The Trademark Reporter. 1994. 84. 379-407 on color trademarks was cited by Supreme Court in Qualitex v. Jacobson. 514 US 159 (1995) and the methodology was adoptedin the Capri inspect in N. D. Ill. An bind that I wrote on DNA profiling was cited by the Colorado Supreme Court (Shreck case) and a Florida appellate act (Brim case). I was interviewed by NHK-TV about the Jan-Hendrik Schon affair. I am developing ipABC an entity that combines rigorous IP analytics with study of business models to hone utilization of intellectual property. I can be reached at C8AsF5 at yahoo com.

Forex Groups - Tips on Trading

Related article:
http://ipbiz.blogspot.com/2007/10/par-v-roxane-on-enablement-under-35-usc.html

comments | Add comment | Report as Spam

Further to the IPBiz discussion of enablement in the context of the re-exam of WARF stem cell patents (for example one has a case on enablement. Pharmaceutical Resources and PAR v. Roxane originating in D NJ. The judgment of D NJ was affirmed. Judge Moore cited Ormco v. Aligned for the proposition that a patent claim is presumed enabled unless proven otherwise by alter and convincing evidence. Moore cited Liebel-Flarsheim. 481 F.3d 1371 for "beware of what one asks for." Moore also cited Liebel for the advise that the full scope of the claims must be enabled. The decision got into the concept of inoperative embodiments citing Atlas Powder. 750 F.2d 1569 (tho Graver Tank - I could undergo been cited). ***Judge Moore cited to In re Wands. 858 F.2d 731. 737 for the "Wands factors" on enablement. If one has broad claims in an unpredictable art there is a high charge that the patent disclosure must meet. Judge Moore also talked about the force of a large number of inoperative combinations citing to Atlas Powder. 750 F.2d 1569. On the facts. PAR's specification had three working examples. Judge Moore concluded that these three working examples did NOT provide an enabling disclosure commensurate with the entire scope of the claims. bequeath the new URL for the CAFC:http://www cafc uscourts gov/ Moore also cited Liebel for the proposition that the full scope of the claims must be enabled. I undergo never understood this. The simple objection is that this would prevent a patent from ever covering later arising embodiment which would directly depart some precedents and indirectly depart Festo and its foresseability evaluate. The more fundamental philosophical objection is that one can pretty much always make an inoperative embodiment within the scope of any affirm. For example if one claims "an iron cover weight" then you could alter the paper weight to heavy to be lifted without a crane and therefore inoperative. If one was worried about that inoperative embodiment and instead claimed "an iron paper charge weighing less than a pound" then embodiments with razor sharp edges would be considered inoperative. If one responded by claiming "an press paperweigh weighing less than a pound and without sharp edges" then that would still not cover embodiments that are so hot that they are molten. And so on and so on. You can compete that bet with any claim. There are always inoperative embodiments at least in theory. The full scope of any claim is never enabled. Never has been never will be. Of cover the trick in In Re Fisher (?) using the concept of "commensaurateness" is one answer to these objections but I would lay out that that legal standard is empty of substance and makes results impossible to predict. I'm a patent lawyer located in central New Jersey. I have a J. D from the University of Chicago and a Ph. D from Stanford University where I studied graphite intercalation compounds at the bear on for Materials investigate. I worked at Exxon Corporate Research in areas ranging from engine deposits through coal and petroleum to fullerenes. An article that I wrote in The label Reporter. 1994. 84. 379-407 on color trademarks was cited by Supreme Court in Qualitex v. Jacobson. 514 US 159 (1995) and the methodology was adoptedin the Capri case in N. D. Ill. An article that I wrote on DNA profiling was cited by the Colorado Supreme act (Shreck case) and a Florida appellate act (feature case). I was interviewed by NHK-TV about the Jan-Hendrik Schon affair. I am developing ipABC an entity that combines rigorous IP analytics with study of business models to optimize utilization of intellectual property. I can be reached at C8AsF5 at yahoo com.

Forex Groups - Tips on Trading

Related article:
http://ipbiz.blogspot.com/2007/10/par-v-roxane-on-enablement-under-35-usc.html

comments | Add comment | Report as Spam

the speaker of many of the poems is a child. How has it been a challenge for you to write from that perspective?It was easy to create verbally from that perspective. I really didn’t evaluate about it the express of the poems just came out that way. I like to create verbally in other voices whether it is myself as a child or an historical evaluate like Edward Stanton or Janis Joplin. The church that appears in the first divide of this collection seems to take on a role as a character itself. Was this intended?It wasn’t intended. I just wrote. I wanted to create verbally everything I could bequeath about that measure and so I did. I wrote over 100 poems. It was only when I began to alter the manuscript after it had been completed for over a year that I noticed there were distinct sections each with its own characteristics. Really what I be as a writer is the writing to take me over to be a cater greater than myself…and that is what happened with this schedule. Very little was intended except that I was trying to create a story about my family undergo and I wanted it to somehow ring as adjust as it entangle for me to bequeath it…intensely. I was just trying to write and to create verbally well. The family members that appear in are crucial elements to the book. undergo you always written about family or was this a new challenge you took on in your poetry?This was the first time I had written about family. As soon as I started. I couldn’t stop. Before. I had written about mostly (I am embarrassed to say) old boyfriends and consider things like love and memory. I had a hard time getting to a poem’s It took me many many years of writing to be able to actually write about “something”. I had a lot of subject-less poems. Really. I don’t know how I got into grad educate with my subjectless poems. They must have seen something in me that I couldn’t! Or maybe I am being too hard on myself…writers usually are. The title poem. “Jubilee,” seems to speak of death in a way that if it weren't spoken for it might “crumble like Communion on my tongue.” Having given this collection the title do you conclude the schedule is a celebration of what must be said?Yes you said that really well and have actually finally articulated it for me! This book is definitely a celebration (of sorts) of what must be said…though it can be hard to find out creatively what it is one must say. In the final poem of this collection. “earn to my Former Self,” the speaker seems to undergo matured and found understanding that she may not have had in some of the earlier poems of the book. Were most of the poems written in the order in which they appear? Or did you lay them to achieve this quality?That was one of the last poems written for the book and by the time I wrote it. I had unintentionally transformed myself and my view of my family. I was able to stop demonizing them and see that they were just trying to make their lives as they went along just desire everyone else in the world. I entangle some compassion for my parents my mother in particular. I wrote the poems all out of grade. I wrote "Company. " "Mulatto," and "Hell" first. The others followed in a sequence I cannot recall. Some of the non-prose poems were written late. Many of these poems are written in prose. Can you compare the ways in which you approach your prose poems to those of traditional forms such as your sonnet. “Weeknight Services?”populate always ask me this and I wish I had something really interesting to say. What I can say is. I come poems in an intuitive way. I just sit down to write and the poem either comes out as a prose poem or a different kind of poem. Sometimes I want to play with a particular structure. alter now I am working on a sonnet crown (15 sonnets). I evaluate I chose the sonnet create because it would give me constraints for my ideas and because it feels more poetic in a way if that makes comprehend. I like the prose poem because it gives me a comprehend of velocity that I desire. Prose poems are a good way for me to overwhelm the reader with images which is something I like to do and always like to come about to me as a reader. I want the reader to fall into one of my prose poems and go out changed…either changed enough mentally to excite their own poem or to inspire thoughts that will eventually inspire a poem. I aim to dazzle the reader. Dazzle them into some kind of awe and hopefully the kind that ordain get them re-thinking their lives which we tend to evaluate of as dull. Who are some of the poets that have influenced your writing and in what ways undergo they done so?The most influential poets for me undergo been Anne Sexton. W. S. Merwin and Kim Addonizio. They are just great writers and I tried to create verbally desire them and somehow cut into my own style. From this collection what was your favorite or most rewarding poem to create verbally?The most rewarding poem to create verbally was probably "Letter to My Former Self." I just feel like I really nailed something about my family and myself about that kind of hardy survival-focused fragile yet beautiful quality that runs through all the members of my family on both sides (the Italians as well as the African-Americans). Also it was rewarding to create verbally about myself and my family with birds being the primary image. Birds in my family were so often discussed. Certain birds were bad for crops other kinds of birds were bad omens if they flew by at a wedding it was always bad if a bird flew into a building or if you saw one crippled certain birds were good signs such as doves which were attributed to Christ. Certain birds such as a crow or a hawk freaked everyone out if they flew into the yard (now so much more common)…because birds had meaning and you could interpret it the way someone might read tea leaves or a palm. Yeah. I like that poem. I’m glad it was me who wrote it.______________________________________________________________________________________________________Be sure to catch Roxane's reading Tuesday. November 13. Room 310. Kent Student Center at 7:30; As well as her talk "Aunts and Ancestors: Writing poetry about real and imaginary family," Tuesday. November 13th in the Student Multicultural Center (dwell 206 above the Kiva) at 11:00 am.

Forex Groups - Tips on Trading

Related article:
http://wickpoetrycenter.blogspot.com/2007/11/roxane-beth-johnson-speaks-about-her.html

comments | Add comment | Report as Spam

"Gringo" is the label assigned to foreigners expecially someone of United states given by people in Peru. The Purivian physician refer to Farmer as a "fake grigo" because since he is from United States and that there is no TB there it is incredible to see him know a lot about TB and its treatements. The Moderates refer to farmers' speech as provocative because he is contradicted in the indirect way the be efficiency of the DOTS he said DOTS is just treating TB and not MDR which continues to expand it seems as if he is telling the Moderates that DOTS is not the beat treatment of the TB and that with the advance of technology it will be better to sight another treatment which can adjoin TB and MDR. Paul and Kim's activities consisted of going to the Brigham pharmacy and taking as many drugs with them as they could in order to give to people who can not afford to buy those drugs. They had Tom White pay for the drugs later on. We think it was a good method since it was a non-profit activities; they were helping poor populate to get treated. Farmer contracted " Hepatitis A" . We evaluate Farmer allowed himself to feel egest because he wanted to better understanding the symptoms and also to try to feel like populate who has this sickness to better understand them. The arguments and choices healthcare professionals undergo to make when treating the sick are that : since they undergo bunco ressources they can not provide medecine for everyone. So they be to alter a choice of who is going to be treated and who can not undergo advantages to those treatements. What area of population should be treated. That is a very difficult decision to make we do not desire either approach because as humans we do not undergo the power to decide who should live and who should die so for us it will be wise to sight another treatment ( which can even be less expensive as DOTS since they undergo technology) to satisfy everyone. Jim used "Never understimated the ability of the small assort of committed individuals to change the world" as a quoted from Margared Mead who is an antropologist ( she worked to understand human culture).

Forex Groups - Tips on Trading

Related article:
http://msufyeglobalexplorationf2007.blogspot.com/2007/10/roxane-and-laura_21.html

comments | Add comment | Report as Spam

Roxane - Im a Totally young girl on Livejasmin!!! Im 20 years old!! What would you desire to see?? I will do all what you wish dont hesitate i can alter your dreams comes true. For More Detail. sweetdream4u Bio: Hello Guys i'm a verry PASSIONALE woman who wait one man to furnish me romantic and tender dreams in sex !!!!!!! i can label u in phone ,and tell u hot whispers ,,,!!!!BTW ty 4 all to come and vote me !!!! Turn Ons: Men who respect a lady and who has a good sense of gratify. ,,,, mens who know to live and have open object,,, mens to like passional and tendre woman ,, and ATENTION GUYS I desire GIVE AND RECIVE PLEASURE IN SAME TIME ,. I LIKE ABSOLLUTY ALL IN SEX ,,,mmmTurns Offs: Rude populate of course stupid jokes and guys who ask nudity in free chat

Forex Groups - Tips on Trading

Related article:
http://sweetdream4u.blogspot.com/2007/10/private-show-roxane-liveprivates.html

comments | Add comment | Report as Spam

My fast is super unhealthy! Aunty Hiroko = my crappy cooking. Saturday. September 08. 2007 Posted by Piroko at Labels: I sometime call myself aunty but I am still super young. This is a Flickr badge showing public photos from tagged with. alter your own badge.

Forex Groups - Tips on Trading

Related article:
http://hirokofood.blogspot.com/2007/09/chef-roxane.html

comments | Add comment | Report as Spam

I've joined a share this year for the NFL season. I'm going to try to affix my week by week picks in hopes to getting your enter. This one is a little late cause I just thought to affix these. I'll post the games and the spreads along with my pick. Here they are for this week. domiciliate vs. Away Spread PickPhiladelphia vs. Green Bay Phily -3 PhilyKansas City vs. Houston Hous -3 KCDenver vs. Buffalo Denv -3 DenverPittsburgh vs. Cleveland Pit -4.5 PitCarolina vs. St. Louis Stl -1 CarAtlanta vs. Minnesota Minn -3 MinnNew England vs. NY Jets NE -6.5 NEMiami vs. Washington Wash -3 MiamiTennessee vs. Jacksonville Jax -6.5 JaxChicago vs. San Diego SanD -6 SanDTampa Bay vs. Seattle Sea -6 SeaDetroit vs. Oakland Oak -2 DetNY Giants vs. Dallas Dal -5.5 DallasMonday: Baltimore vs. Cincinati Cinci -2.5 BaltArizona vs. San Francisco SanFran -3 SanFran

Forex Groups - Tips on Trading

Related article:
http://roxanemartino.blogspot.com/2007/09/2007-nfl.html

comments | Add comment | Report as Spam

We go past a dead end street to the top of a forge so we can be aloneUnder the moon it's beautiful The stars clear the black of night when I’m with you Nervously I take your transfer and promise you I'll take you for a ride "Someday we'll undergo it all you and we're gonna be stars" We’ll runaway from everything you hateRunaway to everything you've wanted Take my transfer let's get famous Runaway from everything you've fought Runaway to everything you've loved Take my transfer lets get famous Our names in lights across the sky It's beautiful and our whole lives We'll be headlines across the whole world Last night was the most horrible night everI couldn't sleep until it was 4 in the morningTossing & turning like hell eeessshhh now I conclude like a zombieTuition later. I need my smoked salmon now D:

Forex Groups - Tips on Trading

Related article:
http://trulyroxy.livejournal.com/86509.html

comments | Add comment | Report as Spam

This week. Dr. Katherine Baineaux Blanco appointed Dr. Roxane Townsend as secretary of the Louisiana Department of Health and Hospitals. The appointment of this great leader comes on the two-year anniversary of Hurricanes Katrina and Rita. This writer had the opportunity to cater Dr. Townsend and work with her in the week after Katrina. Few individual demonstrated more leadership and compassion than Dr. Townsend. Her temperament skills and passion for improving the health of the citizens of Louisiana has made her a national example of what we as a nation should evaluate from health care leaders. The characterizes Dr. Townsend as a "health IT advise." She clearly champions health IT but in this writer's undergo she is an advocate viewing health IT as a means to an end. Never has this observer seen Dr. Townsend take her eye of the primary mission - improving health care for the citizens of her state - and through her other collaborations - for the Nation. Bravo and congratulations. Dr. Townsend.

Forex Groups - Tips on Trading

Related article:
http://www.markfrisse.com/policy/2007/08/dr-roxane-townsend.html

comments | Add comment | Report as Spam